A rare disease known as 14q21.3 deletion syndrome is caused by a lack of genetic information at this chromosome location. Genes are the blueprint for everything that the body needs to function, and are found in the cell nucleus as highly compacted chromosomes. Humans have 23 pairs of chromosomes, one inherited from each parent at birth, with the first 22 encoding general bodily information and a 23rd pair known as the sex chromosomes. Geneticists refer to locations within the chromosomes to better find individual genes by their location. The location code used to denote gene location can be broken down as follows:
In the case of this syndrome, the affected gene lies on chromosome 14, the long arm (q), the 21st band, and a second sub-band within the 3rd banding pattern.
The deletion of 14q21.3 is a very rare condition that affects so few people that there is not a lot of information on this specific type of deletion. However, more general deletions occurring in the 14th chromosome have been studied due to their association with childhood development of oligodendroglioma. This refers to a rare type of brain tumor that develops from glial cells called oligodendrocytes, often from fatty tissue that is supposed to protect the nerve cells in the brain. The development of oligodendroglioma in children is very rare, and has prompted a genetic investigation to find out common causes of this tumor development. While 14q21.3 deletion may not be the specific cause, it likely contributes to oligodendroglioma or is a portion of the deletion of the 14th chromosome.
A rare disease known as 14q21.3 deletion syndrome is caused by a lack of genetic information at this chromosome location. Genes are the blueprint for everything that the body needs to function, and are found in the cell nucleus as highly compacted chromosomes. Humans have 23 pairs of chromosomes, one inherited from each parent at birth, with the first 22 encoding general bodily information and a 23rd pair known as the sex chromosomes. Geneticists refer to locations within the chromosomes to better find individual genes by their location. The location code used to denote gene location can be broken down as follows:
In the case of this syndrome, the affected gene lies on chromosome 14, the long arm (q), the 21st band, and a second sub-band within the 3rd banding pattern.
The deletion of 14q21.3 is a very rare condition that affects so few people that there is not a lot of information on this specific type of deletion. However, more general deletions occurring in the 14th chromosome have been studied due to their association with childhood development of oligodendroglioma. This refers to a rare type of brain tumor that develops from glial cells called oligodendrocytes, often from fatty tissue that is supposed to protect the nerve cells in the brain. The development of oligodendroglioma in children is very rare, and has prompted a genetic investigation to find out common causes of this tumor development. While 14q21.3 deletion may not be the specific cause, it likely contributes to oligodendroglioma or is a portion of the deletion of the 14th chromosome.
This genetic deletion in chromosome 14 is so rare that only a few cases have been reported. In one case study, 12 children were affected by various deletions in their chromosome 14, but only one of them contained the described deletion 14q21.3.
While the exact rare disease symptoms caused by a 14q21.3 deletion is unknown, the cause is this namesake genetic deletion on chromosome 14. This is a random mutation that occurs in offspring spontaneously, and is not inherited genetically from the parents. There are currently so few cases of 14q21.3 deletion that it is difficult to study the effects on the body. However, there are a few gene candidates in this region of the chromosome that if deleted, would have a negative impact on development:
NRXN3 - This gene helps to improve connections between neurons in the brain, and its deletion reduces the release of neurotransmitters that carry important information in the brain.
DIO2 - This gene is expressed in glial cells, and it is hypothesized that deletion of this gene leads to dysregulated glial cells that can form oligodendrogliomas.
TSHR - The thyroid stimulating hormone receptor (TSHR) is responsible for identifying and carrying signals into the thyroid gland to produce the proper hormones for the body. A deletion of this gene could cause a dysfunctional thyroid.
GTF2A1 - This gene produces transcription factors that are necessary for RNA polymerase to read and translate RNA into proteins.
STON2 – The stonin 2 gene encodes a protein that interacts with endocytic machinery proteins EPS15 and intersectin-1 to allow for vesicle endocytosis. This means that these genes are responsible for regulating what is able to enter the cell. Lack of regulation may lead to schizophrenia and tumor progression.
SEL1L – This gene encodes a transmembrane protein found in the endoplasmic reticulum of the cell that is involved in recruiting and translocating substrates of the ER for degradation. This plays an important role in maintaining cell health, and without this gene the cell can undergo transformations that lead to tumor progression.
The symptoms caused by 14q21.3 deletion are not well defined due to a small number of individuals who are affected. However, the appearance of oligodendrogliomas in children is very rare, and many studies have concluded that a deletion somewhere in the 14th chromosome is likely the cause of childhood brain tumor development. One clinical case study connected a 14q21.3 deletion with a glioma tumor present in the frontal lobe of a child’s brain.
While the specific symptoms to this 14q21.3 deletion are not well defined, some symptoms have been identified for more general chromosome 14 deletions. These may include:
Minor abnormalities of the hands and feet
Lip and mouth abnormalities such as cleft lip and palate that make eating, nursing, and talking difficult in young children
Low muscle tone (hypotonia)
Abnormal appearance or development of the face, head, and genitals
Additionally, there are medical concerns that may be associated with this deletion that should be monitored for treatment:
Difficulty growing or gaining weight
Abnormal development of the brain or central nervous system (CNS)
Thyroid dysfunction
Seizures - very rarely associated with this disease
Heart conditions
Respiratory problems
Kidney problems
Hearing and vision impairment
A diagnosis of 14q21.3 deletion depends on a genetic screen to determine if an individual lacks this specific locus in their 14th chromosome. This can be conducted by either karyotyping - the analysis of chromosomes for their length and appearance - or using genomic sequencing - the analysis of specific genes within chromosomes.
The appearance of oligodendrogliomas or other growth abnormalities in young children may indicate the need to seek a medical diagnosis. Before genetic testing, all other potential causes of brain tumors should be explored and ruled out.
Currently, there is no cure or specific treatment for 14q21.3 deletion. Treatment is determined on an individual case basis based on symptoms:
Thyroid dysfunction – thyroxine replacement
Cleft lip/palate – minor surgery
Feeding tubes or laxatives to treat gastrointestinal problems that may arise and to improve weight gain when necessary
Hypotonia – physiotherapy to increase muscle mass
Abnormal development of different body parts – can be corrected by surgery if influencing quality of life
Seizures – anti-epileptic medication
Heart conditions – surgery
Respiratory problems – surgery and extra oxygen provided during recovery
Kidney problems – may require surgery or other forms of treatment in the event of obstruction
Hearing and eyesight – drainage of the ear canal may improve hearing, and vision impairment can be corrected
Depending on the range and severity of symptoms, most young children with 14q21.3 deletion live healthy lives. If the basis of diagnosis is the identification of an oligodendroglioma in the child’s brain, surgery may be required to enable normal development.
https://rarediseases.info.nih.gov/diseases/3722/chromosome-14q-deletion
Dichamp, C., Taillibert, S., Aguirre-Cruz, L. et al. Loss of 14q Chromosome in Oligodendroglial and Astrocytic Tumors. J Neurooncol 67, 281–285 (2004). https://doi.org/10.1023/B:NEON.0000024218.68120.8d
Nauen D, Haley L, Lin MT, Perry A, Giannini C, Burger PC, Rodriguez FJ. Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. Brain Pathol. 2016 Mar;26(2):206-14. doi: 10.1111/bpa.12291. Epub 2015 Aug 14. PMID: 26206478; PMCID: PMC4724334.
Rui Zhang, HanXiao Jiang, YuanJie Liu, GuiQiong He, Structure, function, and pathology of Neurexin-3, Genes & Diseases, 2022, ISSN 2352-3042, https://doi.org/10.1016/j.gendis.2022.04.008
https://www.sciencedirect.com/topics/medicine-and-dentistry/dio2
https://jmg.bmj.com/content/39/2/81
Hey Brandon.
My son is 3,8 years old he have a 14q 21.3 deletion. I´m looking every where on the internet to find something more about it...
I would love to hear from you..
Our son, who is now 3 1/2 years old has been diagnosed with a deleted chromosome and has also been diagnosed as Autistic. I am not having too much luck finding information on this particular chromosome deletion and am wondering if there are others dealing with this same issue or who may have any knowledge of it.
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access.
Enrolling is easy.
After these steps, the enrollment process is complete. All other questions are voluntary. However, these questions are important to patients and their families to create awareness as well as to researchers to study rare diseases. This is why we ask our participants to update their information annually or anytime changes to their information occur.
Researchers can contact CoRDS to determine if the registry contains participants with the rare disease they are researching. If the researcher determines there is a sufficient number of participants or data on the rare disease of interest within the registry, the researcher can apply for access. Upon approval from the CoRDS Scientific Advisory Board, CoRDS staff will reach out to participants on behalf of the researcher. It is then up to the participant to determine if they would like to join the study.
Visit sanfordresearch.org/CoRDS to enroll.
My son was born the 8 of jan. 2014
He has an 14q 21.3 deletion. We are hopping to find other people with these deletion in here.
Blessed parent that is looking for answers and connections. Our son has a rare chromsome deletion 14q21.3. Trying to find a common thread and make connections with other parents to possible work...
Start your own! With a worldwide network of 8,000 users, you won't be the only member of your community for long.
Visit our Frequently Asked Questions page to find the answers to some of the most commonly asked questions.
Created by Brandon Dill | Last updated 12 Oct 2017, 09:07 PM
Join Rareshare to meet other people that have been touched by rare diseases. Learn, engage, and grow with our communities.
FIND YOUR COMMUNITYOur rare disease resources include e-books and podcasts
Community leaders are active users that have been touched by the rare disease that they are a part of. Not only are they there to help facilitate conversations and provide new information that is relevant for the group, but they are there for you and to let you know you have a support system on Rareshare.